Skip to content
Open Access
  • Home
  • Collections
    • High Impact Articles
    • Jawi Collection
    • Malay Medicine
    • Forensic
  • Search Options
    • UiTM Open Access
    • Search by UiTM Scopus
    • Advanced Search
    • Search by Category
  • Discovery Service
    • Sources
    • UiTM Journals
    • List UiTM Journal in IR
    • Statistic
  • About
    • Open Access
    • Creative Commons Licenses
    • COKI | Malaysia Open Access
    • User Guide
    • Contact Us
    • Search Tips
    • FAQs
Advanced
  • Search
  • Observational study of inflamm...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar

Bibliographic Details
Main Authors: Anna Felis-Giemza, Kornelia Chmurzyńska, Jolanta Nałęcz-Janik, Katarzyna Romanowska-Próchnicka, Katarzyna Świerkocka, Mariusz Wudarski, Marzena Olesińska
Format: Article
Language:English
Published: Termedia Publishing House 2019-10-01
Series:Rheumatology
Subjects:
inflammatory arthritis
biologics switching etanercept
biosimilar
Online Access:https://www.termedia.pl/Observational-study-of-inflammatory-arthritis-treatment-by-etanercept-originator-switched-to-an-etanercept-biosimilar,18,38502,1,1.html
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.termedia.pl/Observational-study-of-inflammatory-arthritis-treatment-by-etanercept-originator-switched-to-an-etanercept-biosimilar,18,38502,1,1.html

Similar Items

  • Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
    by: Min-Chan Park, et al.
    Published: (2019-05-01)
  • Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
    by: Janusz Jaworski, et al.
    Published: (2019-05-01)
  • Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature
    by: Madenidou Anastasia-Vasiliki, et al.
    Published: (2019-01-01)
  • Clinical experience with two etanercept biosimilars in Indian patients with spondyloarthritis
    by: Ashok Kumar, et al.
    Published: (2017-01-01)
  • Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
    by: Evelien Moorkens, et al.
    Published: (2020-10-01)

© 2020 | Services hosted by the Perpustakaan Tun Abdul Razak, | Universiti Teknologi MARA | Disclaimer


Loading...